SS-31 (Elamipretide): FDA-Approved Mitochondrial Peptide - Benefits, Dose, Frequency, Cycles
A physician's walkthrough of SS-31 (elamipretide): how it works, its one approved use, off-label ideas, safety data, and his dose, frequency and cycle preferences.
Key moments
Tap a moment to play the video from there.
- 0:46How SS-31 stabilizes mitochondriaStillson explains the electron transport chain, reactive oxygen species and cardiolipin. He says SS-31 binds cardiolipin and helps break a cycle of mitochondrial dysfunction.
- 4:08Barth syndrome and FDA approvalHe describes Barth syndrome as an ultra-rare genetic condition and cites trial results over 168 weeks. He says it is the only approved use.
- 5:33Dementia and brain injury evidenceStillson covers preclinical studies on memory and learning and on brain injury. He notes there is no human data for these uses yet.
- 7:43Kidney disease and diabetesHe cites preclinical kidney studies and one small phase two trial in patients having kidney artery stenting. He says diabetes data are preclinical only.
- 10:12Anti-aging and longevity claimsHe says preclinical studies show better exercise capacity and muscle and heart function. He says there are no lifespan studies, so he frames it as a possible healthspan tool.
- 12:12Human safety trials reviewedStillson lists four long-term or large human trials at 40 mg per day. He says they reported only injection site reactions.
- 14:36Who he would use it forHe ranks brain conditions and kidney disease highest and is less keen on heart failure and macular degeneration. He ties anti-aging use to age and mitochondrial labs.
- 17:28Oral versus injectable formsHe says human data cover IV and subcutaneous use only. He argues oral absorption is unlikely for a four-amino-acid peptide.
- 19:02Dose and cost reasoningHe explains why 40 mg per day may be more than needed outside severe mitochondrial disease. He prefers starting at 5 to 10 mg per day.
- 24:50Cycles and sourcingStillson suggests one month on and one month off for anti-aging as a starting point. He recommends compounding pharmacies over research-use-only sites.
What the video says
Quinn Stillson, an MD who runs the channel, presents SS-31, also called elamipretide, as a synthetic four-amino-acid peptide that targets the mitochondria. He explains that it binds cardiolipin in the inner mitochondrial membrane. In his account, this stabilizes the electron transport chain, which he says supports energy production and reduces reactive oxygen species.
Stillson notes that Barth syndrome is the only FDA-approved use, and he describes trial results in that condition. He then walks through off-label ideas: cognitive decline, traumatic brain injury, chronic kidney disease, diabetes and insulin resistance, chronic fatigue, and general anti-aging. For most of these he says the evidence is preclinical or mechanistic, with no human trials, apart from one small kidney-related trial. He is least enthusiastic about heart failure and macular degeneration, citing weak results in the human studies.
On safety, he cites several long-term human trials at 40 mg subcutaneously per day. In his telling they reported only injection site reactions. He also argues the mechanism, which involves no signaling or growth pathways, makes the safety profile reassuring. He says anti-aging use makes sense mainly from the 50s onward, or earlier if labs show mitochondrial dysfunction.
The last third covers practical choices. Stillson favors subcutaneous injection over oral forms, saying no oral data exist and a four-amino-acid peptide is less likely to be absorbed. He says he would start at 5 to 10 mg per day, partly because of cost, and work up in 5 mg steps to a maximum of 40 mg. He prefers daily dosing to twice-weekly dosing and suggests one month on and one month off for anti-aging as a starting point. He repeatedly says all of this should be done with a doctor and lab monitoring, and he prefers compounding pharmacies to research-use-only sellers.
On each compound
SS-310:46
Stillson describes SS-31 (elamipretide) as a synthetic mitochondrial peptide that binds cardiolipin. He says it is FDA-approved only for Barth syndrome, and that he considers other uses promising but off-label. He discusses dose, frequency, cycling and safety at length.
See how your DNA reads SS-31What this video doesn’t settle
- Most off-label uses discussed, including dementia, brain injury, diabetes and anti-aging, rest on preclinical studies or mechanism, with no human trials cited.
- The 5 to 10 mg starting dose is Stillson's own estimate from cost and scaled preclinical doses, not a dose tested in human trials.
- His claims about oral absorption and chronic fatigue rely on reasoning and anecdote rather than direct studies.
Questions this video answers
What does SS-31 do in the mitochondria according to Quinn Stillson?
Stillson says SS-31 binds cardiolipin in the inner mitochondrial membrane and stabilizes it. In his account, this supports the electron transport chain, improves ATP production and lowers reactive oxygen species.
What dose of SS-31 does Quinn Stillson suggest?
He notes that most human trials used 40 mg subcutaneously per day. For people without severe mitochondrial disease he says he likes starting at 5 to 10 mg per day, increasing in 5 mg steps to a 40 mg maximum, with a doctor's oversight.
Is SS-31 FDA approved?
Stillson says it recently received FDA approval for Barth syndrome only. He says every other use he discusses is off-label.
Does Stillson think oral SS-31 works?
He is not confident. He says there are no human or preclinical studies of oral SS-31 and that its four-amino-acid length makes intestinal absorption less likely, so he sticks with subcutaneous injections.
How long does Stillson say to cycle SS-31?
He points out that human trials ran it continuously for 24 to 168 weeks. For anti-aging he starts with one month on and one month off, and says cycles depend on the individual and use case.
Video by Quinn Stillson MD on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
